Oculis to Present at Upcoming September Investor Conferences

Group 1 - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care, with a differentiated pipeline of innovative product candidates [2] - The company will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference, H.C. Wainwright 26th Annual Global Investment Conference, and Baird Global Healthcare Conference [1] - Oculis' product pipeline includes OCS-01 for diabetic macular edema and post-cataract surgery inflammation, OCS-02 for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [2] Group 2 - The management team of Oculis is experienced and has a successful track record, supported by leading international healthcare investors [2] - The company is headquartered in Switzerland and has operations in the U.S. and Iceland, aiming to improve the health and quality of life of patients worldwide [2] - Interested investors can request one-on-one meetings during the conferences through their respective representatives at the sponsoring institutions [1]